21.5.2021 17:15:01 CEST | ViroGates | Company Announcement

COMPANY ANNOUNCEMENT - No. 12-2021 - 21 May 2021

BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, today announces a capital increase by a nominal amount of DKK 44,657 divided into 44,657 new shares with a nominal value of DKK 1 each, in connection with the exercise of warrants.

ViroGates A/S issued 208,715 warrants in 2015 as a program directed at the board of directors and the management group. The warrants of this program vested over three years. Each warrant entitles the holder to subscribe for one share in the Company with a nominal value of DKK 1. 

Furthermore, ViroGates A/S issued 119,324 warrants in 2019 to four members of management. The warrants of this program vests over four years. Each warrant entitles the holder to subscribe for one share in the company with a nominal value of DKK 1. 

Warrants vested can be exercised during the trading window that opened on 29 April 2021 in connection with ViroGates’ interim financial report for Q1 2020.

ViroGates has received instructions to exercise warrants as follows:

2015 Program:

2019 Program:

Today, ViroGates’ Board of Directors decided to carry out the capital increase relating to the exercised warrants.

The total proceeds to the Company as a result of the subscription of shares amounts to DKK 2,775,525.17

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights from the time of the warrant holder’s exercise notice. ViroGates only has one class of shares.

The new shares are expected to be admitted to trading and official listing on NASDAQ First North Growth Market Copenhagen A/S after registration with the Danish Business Authority during the week commencing 24 May 2021 under the ISIN code for ViroGates A/S’ shares (DK0061030574).

Pursuant to section 32 of the Danish Capital Markets Act, it is hereby announced that the total nominal value of ViroGates A/S’ share capital increases from DKK 3.125.426 to DKK 3,170,083 after the capital increase which is made up of 3,170,083 shares of a nominal value of DKK 1 each, corresponding to 3,170,083 votes. 

The following number of warrants remain under the two programs:
2015 program: 142,196 remaining warrants
2019 program: 108,711 remaining warrants

The announcement can be found at https://www.virogates.com/investor/announcements 

For further information, please contact:

ViroGates A/S:

CEO, Jakob Knudsen

Tel. (+45) 2226 1355, email: jk@virogates.com

Certified Advisor:

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se

About ViroGates

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.

The company was founded in 2000 based on the discovery that suPAR was predictive of the outcome in HIV-infections and subsequently in many other disease areas. Headquartered in Denmark, ViroGates’ sales force covers the Nordics, Spain, and France, while distributors serve other markets.

ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.

About suPAR and suPARnostic®

suPAR is the biomarker detected by ViroGates’ suPARnostic® products and is a protein in plasma, measurable in every human being. suPAR is considered a general risk status biomarker indicating disease presence, disease severity and progression, organ damage and mortality risk across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 600 clinical trials and studies show that the higher the level of suPAR, the worse the prognosis for the patient.

The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing demands on health systems globally and tightening healthcare budgets necessitate efficiency improvements and innovative solutions in hospitals. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by 34% and reducing the average hospital length-of-stay by 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Roche Diagnostics’ cobas, instruments, Siemens ADVIA XPT instruments and the Abbott Labs Architect and Alinity instruments. ViroGates works with partners to develop solutions for other platforms.

Disclosure regulation

Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.

Contacts

• Jakob Knudsen, CEO, +45 2226 1355, jk@virogates.com

Attachments

• 20210521-ViroGates Company ann. 12.pdf